Lupin Ltd

- The company has the ability to borrow about USD 1.5 billion - 1.6 billion in addition to cash on its balance sheet. - Planned capital allocation focuses on specialty assets with a typical investment range of USD 250 million - 300 million per asset, possibly higher depending on opportunities. - Threshold limits have been defined for investments in adjacencies to control expenditure. - There is interest in acquiring assets both in the U.S., Europe, and India within the specified investment range. - No explicit mention of equity fundraising was made in the provided transcript. - Overall, the focus appears to be on debt borrowing for acquisitions and investments rather than immediate equity fundraising.

- Lupin has the ability to borrow about USD 1.5 billion - 1.6 billion apart from existing cash. - Capital allocation priorities include acquiring specialty assets in the USD 250 million - 300 million range, possibly more depending on opportunities. - Focus on specialty assets in India with a similar sweet spot of about USD 250 million - 300 million. - Interested in assets in U.S., Europe, and developed markets like VISUfarma acquisition. - Considering clinical-stage assets requiring investment before market launch. - Strategic investments target specialty frontiers like respiratory, neurology, and ophthalmology. - Maintaining disciplined capital allocation aligned with long-term growth drivers including specialty and complex platforms.

Future growth expectations for Lupin's sales/revenue/volumes: - India business aims for continued double-digit growth, targeting 20%-30% above market growth, driven by chronic therapies and new initiatives like added salesforce and innovative products (Page 17). - Emerging markets expected to grow strongly, with Brazil doubling sales due to products like Dapagliflozin (Page 19). - US business shows sustained growth, with 46% YoY increase in the recent quarter, driven by new product launches and biosimilars pipeline, including Pegfilgrastim starting FY27 (Pages 5, 9). - EBITDA margins expected at 24%-25% for FY27 with strong top-line buoyancy and cost focus (Page 12). - Specialty and complex products, including Semaglutide and biosimilars, planned for launch over next few years, contributing to growth (Pages 9, 11). - R&D investments to continue increasing to support complex projects and specialty segments (Page 14). - VISUfarma acquisition to add ~EUR 60 million revenue from next quarter, boosting Other Developed Markets' share (Page 18).

- Lupin expects to maintain robust top-line growth driven by new products like Mirabegron, Tolvaptan, and biosimilars (Pegfilgrastim, Ranibizumab). - EBITDA margins are guided around 24%-25% for FY27, despite competitive pressures, with focus on cost control and R&D investments (~7.5%-8.5% of sales). - The US business is expanding through specialty product acquisitions and organic launches, targeting doubling the share of complex products in coming years. - India prescription business is expected to sustain double-digit growth, supported by chronic therapies constituting 67% of portfolio. - Emerging markets, notably Brazil, show strong growth (Brazil doubled in turnover). - New product launches, including Semaglutide in India (potential INR 1,500 crore opportunity in year one), are expected to contribute positively. - Overall optimism to close FY26 strongly and maintain growth momentum into FY27 and beyond.

The transcript from the Lupin Limited Q3 FY26 Earnings Call does not explicitly mention the current or expected order book or pending orders. However, key points related to business outlook and growth opportunities include: - Specialty assets acquisitions planned, with a borrowing capacity of USD 1.5 - 1.6 billion and preferred deal sizes around USD 250 - 300 million. - Strong product pipeline with new launches such as Pegfilgrastim biosimilar in the US, and ongoing R&D including Nexplanon® (planned FY28 filing). - Emerging Markets, especially Brazil, showing high growth (Brazil nearly doubled turnover this quarter). - India prescription business growing around 10.9% YoY in Q3; chronic segment now 67% of portfolio. - Continued focus on expanding specialty and complex platform products to sustain growth. No specific figures or updates on order book or pending orders are disclosed in the provided transcript.